Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus (DÁLIA)

National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus

The purpose of this study is to evaluate the efficacy and safety of LID104 in the treatment of type 2 diabetes mellitus.

Study Overview

• Status: Not yet recruiting
• Conditions: Type 2 Diabetes Mellitus
• Intervention / Treatment: Drug: LID104; Drug: Dapagliflozin; Drug: Linagliptin

• Study Type: Interventional
• Enrollment (Estimated): 597
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Alexandra F D Alves, MSc; Phone Number: +55 1938878917; Email: pesquisa.clinica@ncfarma.com.br

Study Locations

• Brazil
  • SP
    • Hortolândia, SP, Brazil
      • Investigational Site
      • Contact: Alexandra F D Alves, MSc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the consent form;
• Diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goal of HbA1c with previous dietary, physical exercise and monotherapy with the maximum tolerated dose of metformin at a stable dose in the last 3 months and which, in the Investigator's discretion, may benefit from the addition of the trial drugs.
• Participants with HbA1c ≥ 7.5% and ≤ 10.5% at the screening visit.
• Participants with body mass index ≤ 45 kg/m2

Exclusion Criteria:

• Any clinical observation or laboratory condition finding that is interpreted by the investigating physician as a risk to the participation of the research participant in the clinical trial or presence of uncontrolled chronic disease(s);
• History of alcohol and/or illicit drug use disorder in the last two years;
• Participants who are pregnant, nursing or planning to become pregnant, or female participants of childbearing potential who are not using reliable contraception;
• Participants with known allergy or hypersensitivity to the components of the drugs used during the clinical trial;
• Participants with a current medical history of cancer and/or treatment for cancer in the last five years;
• Participation in a clinical trial protocols in the last 12 months (CNS Resolution 251, of August 7, 1997, item III, subitem J), unless the investigator judges that there may be a direct benefit at the same;
• Type 1 Diabetes Mellitus;
• Fasting glucose above 300 mg/dL;
• Participants who have risk factors for severe volume depletion;
• Participants on dialysis;
• History of metabolic acidosis and/or using medications that may cause lactic acidosis;
• Participants who have had a cardiovascular event (acute myocardial infarction, acute coronary syndrome, recent onset of stable angina, stroke, unstable congestive heart failure requiring change in treatment), who underwent a revascularization procedure or vascular surgery in the six months prior to screening;
• Known heart failure, class III to IV (New York Heart Association);
• Moderate or severe renal insufficiency;
• Participant with altered liver function, defined by serum levels of aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase above three times the upper limit of normal or bilirubin > 1.5 times the upper limit of normal;
• Participants who underwent bariatric surgery in the last two years and/or other gastrointestinal surgeries that may cause chronic malabsorption;
• Medical history of haemoglobinopathies, blood dyscrasia or any other hemolytic disorders;
• Known medical history of pancreatic diseases that may suggest insulin deficiency;
• Known uncontrolled hypothyroidism or hyperthyroidism or thyroid-stimulating hormone (TSH) dosage greater than 1.5 times the reference value;
• Known history of sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte changes or uncontrolled seizures in the six months prior to trial screening, or any other condition that, in the judgment of the investigator, may favor clinically significant alterations in the levels of the enzyme creatine phosphokinase (CPK) or participants with CPK dosages greater than ten times the value considered for normality;
• Participants who started treatment with anti-obesity drugs less than three months ago or with a dose change in the last three months;
• Participants with current and prolonged treatment for more than fifteen days with systemic steroids at the time of informed consent or in the last three months prior to the screening visit;
• Participants on insulin therapy or using oral antidiabetics other than metformin;
• Participants using prohibited medications according to the study protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LID104; The patient must take 1 tablet of LID104 plus 1 tablet of placebo of dapagliflozin and 1 tablet of placebo of linagliptin once a day.	Drug: LID104; Experimental
Active Comparator: Dapagliflozin; The patient must take 1 tablet of dapagliflozin plus 1 tablet of placebo of LID104 and 1 tablet of placebo of linagliptin once a day.	Drug: Dapagliflozin; Active comparator
Active Comparator: Linagliptin; The patient must take 1 tablet of linagliptin plus 1 tablet of placebo of LID104 and 1 tablet of placebo of dapagliflozin once a day.	Drug: Linagliptin; Active comparator

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Glycated hemoglobin (HbA1c)	Change from baseline in glycated hemoglobin	120 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Fasting blood glucose	Change from baseline in fasting blood glucose	120 days
HbA1c reduction to < 7%	Proportion of participants with HbA1c reduction to < 7%	120 days
Treatment failure	Proportion of participants who were discontinued from the study because they needed medication other than the study medication for blood glucose control	Up to 140 days
Body weight	Change from baseline in body weight	Up to 140 days
Blood pressure	Change from baseline in blood pressure	Up to 140 days

Collaborators and Investigators

• Sponsor: EMS

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2024
• Primary Completion (Estimated): May 1, 2026
• Study Completion (Estimated): January 1, 2027

Study Registration Dates

• First Submitted: May 23, 2023
• First Submitted That Met QC Criteria: May 23, 2023
• First Posted (Estimated): June 2, 2023

Study Record Updates

• Last Update Posted (Estimated): June 2, 2023
• Last Update Submitted That Met QC Criteria: May 23, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Protease Inhibitors; Incretins; Sodium-Glucose Transporter 2 Inhibitors; Dipeptidyl-Peptidase IV Inhibitors; Dapagliflozin; Linagliptin
• Other Study ID Numbers: LID104-III-0123

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No